Research progress of anti-IGE treatment for allergic rhinitis

Allergic rhinitis (AR) is an inflammatory reaction of the nasal mainly mediated by Immunoglobulin E(IgE). It is one of the most common chronic diseases in the world. Patients with nasal discomfort, persistent nasal itching, sneezing, runny nose and so on as the main symptoms, it is a refractory allergic disease, will seriously reduce the quality of life of patients.

At present, the treatment of patients with allergic rhinitis is mainly to avoid contact with allergens, drug treatment and desensitization treatment. The serum IgE level of most patients is significantly increased. By introducing monoclonal antibodies into the gene-expression environment of IgE, the levels of free IgE can be effectively suppressed, resulting in a significant reduction in the incidence of AR. Therefore, this article will explore the mechanism and clinical application of this new anti-IgE drug, omalizumab.

Omalizumab can significantly relieve the condition of AR patients and reduce the dosage of corticosteroids and antihistamines, but its long-term efficacy and safety need further observation and analysis. Before use, the patient's status should be confirmed and the potential risks should be discussed with the patient in advance.